A股首份2025年年报出炉：沃华医药净利润大增162.93%

Core Insights - Shandong Wohuah Pharmaceutical Technology Co., Ltd. is the first A-share listed company to disclose its 2025 annual report, showing a revenue of 817 million yuan, a year-on-year increase of 6.96%, and a net profit attributable to shareholders of 95.71 million yuan, a significant increase of 162.93% [2] Group 1: Financial Performance - In 2025, the company achieved a revenue of 817 million yuan, reflecting a growth of 6.96% year-on-year [2] - The net profit attributable to shareholders reached 95.71 million yuan, marking a substantial increase of 162.93% compared to the previous year [2] Group 2: Product Portfolio and Market Strategy - Wohuah Pharmaceutical has developed a product matrix covering over ten therapeutic areas, with 161 drug approval numbers and 15 exclusive products [2] - Key products such as Wohuah® Xinkeshu Tablets and Bone Health Capsules are central to the company's revenue and profit [2] - The company has established a qualification access system, with 91 products included in the national medical insurance directory and 43 in the national essential drug list, creating a multi-layered product barrier [2] Group 3: Marketing and Sales Channels - The company is expanding its marketing system to grassroots and outpatient markets, with its core product Wohuah® Xinkeshu Tablets newly entering 165 county-level medical community directories [2] - In 2025, revenue from the outpatient market reached approximately 103 million yuan, accounting for 12.6% of total revenue, with e-commerce sales growing by 113% year-on-year [3] Group 4: Operational Efficiency and Management - Wohuah Pharmaceutical is implementing a refined management strategy aimed at reducing costs while increasing sales, efficiency, and cash flow [3] - The company is also focusing on the intelligent upgrade of its production system and supply chain, optimizing capacity layout and inventory turnover efficiency [3] Group 5: Shareholder Returns and Future Outlook - The company plans to distribute a cash dividend of 1.46 yuan per 10 shares (including tax) to its shareholders [4] - Looking ahead, Wohuah Pharmaceutical aims to maintain strategic focus on traditional Chinese medicine and leverage its solid financial structure for potential capital operations [4]